APA (7th ed.) Citation

V, L., J, L., C, L., K, J., M, M., S, S., & N, B. (2024). Descriptive analysis of durvalumab use in unresectable stage III non-small cell lung cancer in patients treated in Quebec's University teaching hospitals. Frontiers in oncology, 14, 1506172. https://doi.org/10.3389/fonc.2024.1506172

Chicago Style (17th ed.) Citation

V, Labrie, Lefebvre J, Labbé C, Jao K, Malick M, Simard S, and Bouchard N. "Descriptive Analysis of Durvalumab Use in Unresectable Stage III Non-small Cell Lung Cancer in Patients Treated in Quebec's University Teaching Hospitals." Frontiers in Oncology 14 (2024): 1506172. https://doi.org/10.3389/fonc.2024.1506172.

MLA (9th ed.) Citation

V, Labrie, et al. "Descriptive Analysis of Durvalumab Use in Unresectable Stage III Non-small Cell Lung Cancer in Patients Treated in Quebec's University Teaching Hospitals." Frontiers in Oncology, vol. 14, 2024, p. 1506172, https://doi.org/10.3389/fonc.2024.1506172.